CD79A and infection: Furthermore, when OPERA I/II data were pooled with those from the ORATORIO trial in PPMS, an association was observed between decreased IgG, IgM, and IgA levels and an increased risk of serious infection in ocrelizumab-treated participants, which was strongest for IgG and less pronounced for IgM or IgA [36].